Skip to content

US · SPRY · BIOTECHNOLOGY

ARS Pharmaceuticals, Inc. (SPRY) intrinsic value and stock valuation

$2.96as of 2026-11-21 · Mkt cap 532.27M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

ARS Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values SPRY with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SPRY’s statements →

ARS Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92130 ars-pharma.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$84.3M+36.4% 5y CAGRd
20182025
Net income
-$-171.3M
20182025
Free cash flow
-$-171.21M
20182025
Total equity
$114.3M
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$84.3M$89.2M$30K$1.32M$5.51M
Operating income-$-179.45M-$-3.08M-$-67.52M-$-35.52M-$-19.45M
Net income-$-171.3M$8M-$-54.37M-$-34.68M-$-20.24M
EPSd-$-1.74M$78.1K-$-570.99K-$-867.87K-$-701.07K
Operating cash flow-$-170.87M$13.6M-$-59.27M-$-40.08M-$-17.56M
Capital expenditure-$-340K-$-560K-$-170K-$-200K-$-60K
Free cash flow-$-171.21M$13M-$-59.44M-$-40.28M-$-17.62M
Total assets$327.7M$351.2M$233.2M$281.4M$61.5M
Total debt$96.4M$40K$270K$480K$9.03M
Net debt$55.1M-$-50.77M-$-70.7M-$-210.04M-$-51.03M
Total equity$114.3M$256.8M$230.8M$272.9M-$-31.27M
Cash and short-term investments$245M$314M$228.4M$274.4M$60.1M
Income statement
20252024202320222021
Revenue$84.3M$89.2M$30K$1.32M$5.51M
Cost of revenue$20.4M$20.6M$0.00$17.1M$210K
Gross profit$63.9M$68.6M$30K-$-15.8M$5.29M
Research and development expenses$13.2M$19.6M$20.3M$18.4M$20.3M
Selling, general and administrative expenses$230.1M$0.00$47.3M$18.7M$4.69M
Other expenses$0.00$52.1M$0.00-$-17.32M-$-210K
Operating expenses$243.3M$71.7M$67.6M$19.7M$24.8M
Cost and expenses$263.7M$92.2M$67.6M$36.8M$25M
Interest income$10.7M$0.00$0.00$0.00$800K
Interest expense$2.6M$0.00$0.00$0.00$110K
Depreciation and amortization$1.37M$80K$70K$320K$210K
Ebitda-$-167.41M$8.37M-$-54.29M-$-34.36M-$-19.92M
Operating income-$-179.45M-$-3.08M-$-67.52M-$-35.52M-$-19.45M
Total other income/expenses, net$8.07M$11.4M$13.2M$830K-$-790K
Income before tax-$-171.38M$8.29M-$-54.37M-$-34.68M-$-20.24M
Income tax expense-$-80K$290K$0.00$0.00$0.00
Net income-$-171.3M$8M-$-54.37M-$-34.68M-$-20.24M
Weighted average shares outstanding$98.6M$96.9M$95.2M$40M$28.9M
Weighted average diluted shares outstanding$98.6M$102.4M$95.2M$40M$28.9M
Balance sheet
20252024202320222021
Cash and short-term investments$245M$314M$228.4M$274.4M$60.1M
Net receivables$26.4M$9.16M$800K$0.00$0.00
Inventory$8.37M$5.21M$0.00$0.00$0.00
Total current assets$284.9M$334.3M$231.6M$277.7M$60.7M
Property, plant and equipment, net$2.46M$1.07M$820K$770K$690K
Goodwill and intangible assets$14.5M$7.68M$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$42.8M$16.9M$1.62M$3.73M$720K
Total assets$327.7M$351.2M$233.2M$281.4M$61.5M
Accounts payable$5.72M$9.87M$760K$1.66M$1.79M
Short-term debt$0.00$40K$240K$230K$3.62M
Deferred revenue$610K$560K$0.00$0.00$1.46M
Total current liabilities$39.2M$23.4M$2.39M$5.44M$8.19M
Long-term debt$96.4M$0.00$40K$250K$5.41M
Deferred revenue, non-current$1.13M$1.53M$0.00$0.00$3M
Total non-current liabilities$174.3M$70.9M$40K$3.1M$84.5M
Capital lease obligations$0.00$40K$40K$480K$620K
Total liabilities$213.4M$94.4M$2.43M$8.55M$92.7M
Common stock$10K$10K$10K$10K$0.00
Retained earnings-$-294.6M-$-123.31M-$-131.3M-$-76.94M-$-42.26M
Accumulated other comprehensive income (loss)$120K$220K$50K$410K$0.00
Total equity$114.3M$256.8M$230.8M$272.9M-$-31.27M
Total investments$203.7M$263.2M$157.4M$63.9M$0.00
Total debt$96.4M$40K$270K$480K$9.03M
Net debt$55.1M-$-50.77M-$-70.7M-$-210.04M-$-51.03M
Cash flow statement
20252024202320222021
Net income-$-171.3M$8M-$-54.37M-$-34.68M-$-20.24M
Depreciation and amortization$1.37M-$-7.17M$70K$320K$210K
Stock-based compensation$22.1M$14.5M$9.23M$5.84M$2.83M
Change in working capital-$-20M-$-1.81M-$-7.33M-$-12.75M-$-360K
Accounts receivable-$-17.2M-$-8.18M$0.00$0.00$0.00
Inventory-$-21.99M-$-5.95M$0.00$0.00$0.00
Accounts payable$18.9M$16.4M-$-2.78M-$-10.29M$0.00
Net cash provided by operating activities-$-170.87M$13.6M-$-59.27M-$-40.08M-$-17.56M
Investments in property, plant and equipment-$-340K-$-560K-$-170K-$-200K-$-60K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$56.8M-$-106.1M-$-87.18M-$-200K-$-60K
Common stock issued$5.68M$3.02M$6.9M$570K$170K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$104.6M$72.4M$6.9M$190.7M$53.2M
Net change in cash-$-9.5M-$-20.15M-$-139.55M$150.5M$35.5M
Cash at end of period$41.3M$50.8M$71M$210.5M$60.1M
Operating cash flow-$-170.87M$13.6M-$-59.27M-$-40.08M-$-17.56M
Capital expenditure-$-340K-$-560K-$-170K-$-200K-$-60K
Free cash flow-$-171.21M$13M-$-59.44M-$-40.28M-$-17.62M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About ARS Pharmaceuticals, Inc.

        ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.

        CEO
        Donn Casale
        Employees
        163
        Beta
        0.88

        Explore

        Frequently asked questions

        What is the intrinsic value of ARS Pharmaceuticals, Inc. (SPRY)?

        InvestorsCraft does not currently publish an intrinsic value for SPRY. How the IC value is calculated.

        Is SPRY undervalued?

        InvestorsCraft does not publish an undervaluation signal for SPRY at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.